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Abstract
The role of antibiotic exposure in the evolution and emergence of resistance is challenging to assess. We used carbapenem-resistant
Pseudomonas aeruginosa (PA) phenotypes to assess possible factors that are associated with the occurrence and prognosis of such a
phenotype and to examine the possible contribution of antibiotic exposure to the evolution of antimicrobial resistance. We conducted a
nested case-control study. Cases were deﬁned as patients from whom carbapenem-resistant ureidopenicillin-sensitive PA (CRUS-PA) was
isolated; matched controls were PA patients who did not have isolation of CRUS-PA. We analysed potential predictors of CRUS-PA
isolation and assessed their clinical signiﬁcance (mortality and eventual isolation of pan-resistant PA), taking into account antibiotic
exposures. We matched 800 case-control pairs. Case patients were more likely to have been exposed to anti-PA carbapenems (OR = 6.9;
95% CI, 2.5–18.6). This ﬁnding did not apply to the administration of other antibiotics. The mortality among CRUS-PA patients was similar
to that of the controls (HR, 0.8 95%; CI, 0.6–1.1). Subsequent isolation of pan-resistant PA was more frequent among case patients
compared with non-pan-resistant controls (p-value <0.05). Among cases, the risk of eventual pan-resistant PA isolation was increased in
ertapenem recipients, only after and not prior to the index specimen date (HR, 1.9, 95%; CI, 1.01–3.4). Therefore we suggest that the
CRUS-PA phenotype may represent pan beta-lactam resistance and that antibiotic exposure is associated with evolution of PA resistance
phenotypes. We demonstrate a novel association of ertapenem with sequentially appearing PA resistance patterns.
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Introduction
Pseudomonas aeruginosa (PA) is a known major bacterial
pathogen. Although it occasionally causes community-acquired
infections, it is a signiﬁcant medical burden in hospital settings,
where it may be resistant to a wide range of antibiotics [1].
Beta-lactam antibiotics are considered the mainstay of treat-
ment for PA. In severe infections, some recommend double
antibiotic coverage including non-beta-lactam antibiotics [2].
The major classes of beta-lactam antibiotics available for the
treatment of PA include: ureidopenicillins; third and fourth
generation cephalosporins (e.g. ceftazidime and cefepime); and
carbapenems (such as imipenem, meropenem and doripenem),
though ertapenem is not considered to be an effective
treatment [2]. Mechanisms of resistance to different beta-lac-
tam agents vary and beta-lactam pan-resistance has been
documented [1,3].
Recently, it was suggested that patient exposure to either
imipenem or ciproﬂoxacin is associated with development of
PA infections with wider resistance proﬁles [4]. Patient--
to-patient transmission of carbapenem-resistant PA can also
account for these infections in intensive care settings [5].
Antibiotic pressure is regarded by many as the culprit that
induces antibiotic resistance at the single bacteria level as well
as an ecological pressure that promotes the spread of such
bacteria. Measures to curtail inappropriate antibiotic
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prescription and encourage prudent use are promoted at
institutional and national levels [6,7]. However, information on
the effect that antibiotics have on a patient and their
contribution to the development of resistant bacteria in that
same patient is not widely available. The ecological trends are
population centred and not patient centred. In fact there is a
dearth of evidence of the individual probabilities of beneﬁts/
harms patients might experience with regard to emergence of
resistance in their ﬂora.
In our institution, we have noticed that in recent years
there has been an increased proportion of Pseudomonas
aeruginosa isolates that display a unique susceptibility/resis-
tance phenotype – carbapenem resistance and ureidopeni-
cillin sensitivity. Until 2002 they comprised no more than
5% of all Pseudomonas aeruginosa isolates. Since 2002 their
prevalence has varied between 5% and 8.7% (see Table S2
and Fig. S1). The possibility of ureidopenicillin therapy for a
carbapenem-resistant pathogen is unique. However, if the in
vitro phenotype does not predict an in vivo response, other
therapeutic options should be sought. Here we assess
whether this phenotype was unique to certain patients and
whether it might have different prognostic implications from
other clinical PA isolates. Additional aims for this study
were to evaluate whether speciﬁc antibiotic exposure can
be related to the isolation of this unique phenotype or
other PA resistance phenotypes. The main foundations for
this study were a reliable and substantive dataset based on
both a long-standing antibiotic stewardship programme in
our institution, which also documents all antibiotic
prescriptions, and our computerized microbiological data-
base.
Methods
The study was performed at the Hadassah-Hebrew University
Medical Centre, Jerusalem, Israel, a tertiary care medical
institution comprising two hospital campuses and a total of
1100 inpatient beds (the larger campus has 775 beds), and was
approved by the institutional ethics committee. The institution
gives care to both admitted and daycare patients and does not
deliver primary outpatient care, which is delivered by the
community physicians as part of the patients’ Health
maintenance organizations. The clinical, microbiological and
pharmacy data included in this study were collected from the
institutional database between January 1987 to August 2009.
Our institution has maintained an antibiotic stewardship
programme for over 25 years. Part of this programme includes
scrutiny and approval of selected antibiotic prescriptions by
infectious diseases consultants. All relevant orders and
approvals have been computerized and documented since
1987. The microbiology laboratory computerized database
also dates back to 1987.
Patients were included according to the protocol presented
in Fig. 1. Using the WHONET software package [8] we
reviewed the entire clinical microbiological database and
identiﬁed PA cultures that were tested for susceptibility to
one or more carbapenems used in our institution (imipenem
and meropenem) and ureidopenicillins (piperacillin, azlocillin
and mezlocillin). For some years only one carbapenem or
ureidopenicillin was in use.
Carbapenem-resistant ureidopenicillin-susceptible PA
(CRUS-PA) was deﬁned as a P. aeruginosa that was resistant
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FIG. 1. Flow chart depicting the selection process of the included cases and controls in the analysis.
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to either imipenem or meropenem (most of the time only one
of the two was tested) and susceptible to ureidopenicillins. For
the purpose of this analysis we classiﬁed intermediate resis-
tance as resistant. Carbapenem-resistant ureidopenicillin-resis-
tant PA (CRUR-PA) was deﬁned when a PA isolate was
non-susceptible to both antibiotic groups (see Table S1). We
deﬁned a patient’s ﬁrst CRUS-PA-positive specimen as the
index specimen and the date of specimen collection as the
index date. Patients with PA isolates, but from whom
CRUS-PA was never isolated, were used for the control pool.
The control pool contained any PA isolates that were
carbapenem-sensitive and ureidopenicillin-sensitive (CSUS),
carbapenem-sensitive and ureidopenicillin-resistant (CSUR)
or carbapenem-resistant and ureidopenicillin-resistant
(CRUR), but never contained isolates that were CRUS. Cases
and controls were matched for sex, year of specimen
collection, hospital campus and type of ward in which the
specimen was collected. All potential controls were stratiﬁed
according to the matching criteria and randomly sampled to
generate the study controls. Specimens were included if all
such data were available. When a case and control were
matched, the control’s matched specimen was considered his
index specimen and the specimen date, the index date.
Data collection included demographic data (date of birth,
sex and date of admission) and laboratory data within 48 h of
specimen collection: white blood cell count, serum albumin,
serum creatinine, serum urea and haemoglobin levels. Expo-
sure to all classes of antibiotics since 1987 at our institution
was assessed. Each patient’s exposure to antibiotics was
estimated in two ways: whether the patient received an
antibiotic on a speciﬁc day (yes/no), and the patient’s antibiotic
load, deﬁned as the total number of days each patient had
received an antibiotic in the 60 days prior to and following the
index date. The antibiotic resistance proﬁle of each PA isolate
was recorded as well as specimen source. Nosocomial
acquisition was determined if the specimen was collected
more than 72 h after admission.
All cultured bacteria were processed according to NCCLS/
CLSI guidelines. [9] The cut-off values for sensitive/interme-
diate/resistant designation did not change over the study
period. In our laboratory, most often either imipenem discs
(1302 isolates) or sometimes meropenem discs were used
(303 isolates in the years 2003–2006) to assess carbapenem
susceptibility. Rarely, both were used (ﬁve isolates). In only
one case was the isolate imipenem resistant but meropenem
sensitive, and deemed carbapenem resistant. Ureidopenicillin
susceptibility was assessed with three discs during the study
period: azlocillin discs were used between 1987 and 1995 (177
isolates), mezlocillin discs were used between 1987 and 2002
(504 isolates) and piperacillin discs were used between 1991
and 2010 (1100 isolates). There were four isolates that were
assessed with piperacillin and azlocillin, all sensitive to both.
There were another four isolates that were assessed with
piperacillin and mezlocillin; all four were sensitive to both. All
isolates that were assessed with azlocillin were also assessed
with mezlocillin. In 171 isolates (97%) there was complete
concordance between the isolates. There were six that were
mezlocillin resistant and azlocillin sensitive and were consid-
ered ureodopenicillin resistant in our analysis.
During the entire study period there has been an active
antimicrobial stewardship programme encompassing all ser-
vices in the hospital. In this programme each department is
visited by an infectious diseases specialist every 2 days and
antibiotics are distributed only if the infectious diseases
specialist approves dispensing by the hospital pharmacy.
During the study period, in the hospital formulary, at least
one ureidopenicillin was available. Carbapenems were intro-
duced in 1990. Ertapenem was introduced in 2003. Standard
precautions were and are used when treating patients carrying/
infected with multidrug-resistant Pseudomonas aeruginosa.
Statistical analysis
Continuous variables were compared using the paired t-test
whereas categorical variables were compared with the
McNemar test. All comparisons were performed between
patients from whom CRUS-PA was isolated and those patients
from whom it was not. As the cases and controls were
matched, conditional logistic regression was performed in
order to assess risk factors for CRUS-PA vs. non-CRUS-PA
phenotype. All variables collected were entered into the initial
model. Additionally, only variables that were closely associated
with the CRUS-PA phenotype on univariate analysis
(p-value <0.2) were assessed in a separate model. In cases of
multi-colinearity the variables with greater variability were
included in the models. Prognosis as a major outcome was
measured with time from index date to death or censorship. A
secondary outcome was a later isolation of CRUR-PA. Kaplan–
Meier survival curves were generated and compared with the
log-rank test. Additionally, matched stratiﬁed Cox propor-
tional hazard models were employed for multivariate survival
analysis. In all analyses, p-values <0.05 were deemed statisti-
cally signiﬁcant. Analyses were performed with SPSS version
19 (SPSS Inc., Chicago, IL, USA).
Results
During the 22-year study period, 65 226 PA-positive cultures
were analysed. There were 57 518 (88.2%) PA culture
records, obtained from 18 886 patients, that were tested for
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O188–O196
O190 Clinical Microbiology and Infection, Volume 20 Number 3, March 2014 CMI
carbapenem and ureidopenicillin susceptibility (Fig. 1). A total
of 9365 cultures (12% of all cultures) collected from 2499
patients (13% of all patients) were carbapenem resistant and of
these, 2426 cultures (25% of carbapenem-resistant PA cultures
and 4.2% from all PA tested for both carbapenems and
ureidopenicillins) from 990 patients (39% of all patients with
carbapenem-resistant PA) were ureidopenicillin susceptible.
Carbapenem resistance among PA emerged during the
mid-1990s (Fig. S1a). Among the carbapenem-resistant PA,
the proportion of CRUS-PA showed variability over the years
(Fig. S1b; Table S2), ranging between 7% and 49%. After
excluding patients with missing data, there were 956 patients
(5.4% of all 18 886 patients) from whom CRUS-PA was
isolated and were potential cases for the study (Fig. 1). We
found 800 matched controls for CRUS-PA-positive patients
and these 1600 patients comprised the study sample for
analysis.
Each group included 319 females (40%). In each group 93
(12%) patients were hospitalized at the smaller campus. There
was also matching in the in-hospital location of patients: 321
(40.1%) case-control pairs were in ICUs, 163 (20.4%) were in
internal medicine wards, 163 (20.4%) in surgical wards, 51
(6.4%) were from the emergency department, 48 (6%) were
paediatric and the remaining 54 pairs were distributed amongst
other clinical services. Characteristics of cases and controls
are presented in Table 1. The index specimens were more
often from urine and sputum, were less often designated as
community acquired and originated from younger patients and
those whose blood creatinine levels were slightly higher.
We compared the susceptibilities of the initial PA isolates in
cases and controls (Table 2). Interestingly, the CRUS-PA
isolates, as a group, were more resistant to a variety of
non-beta-lactam antibiotics (including aminoglycosides and
ﬂuoroquinolones) compared with the control group
(p <0.005). They were more resistant to ceftazidime and
aztreonam (p = 0.08 and 0.04).
In order to understand whether there was a possible
association (either prior to or following the index date)
between antibiotic exposure (e.g. carbapenem administration)
and the CRUS-PA phenotype, we examined the antibiotic
prescriptions given to the cases and controls before and after
the isolation of the index culture. CRUS-PA cases were more
likely to be exposed to carbapenems both prior to and after
the index date (Table 3). This was also true for exposure to
ureidopenicillins. The frequency of antibiotic exposure 60 days
prior to and following specimen collection is presented in
Fig. 2. Antibiotic load was also higher in the CRUS-PA patients
(Fig. S2). Assessment of possible risk factors for the occur-
rence of CRUS-PA vs. non-CRUS-PA, using multivariate
analyses, conﬁrmed that prior treatment with anti-PA carba-
penem was associated with CRUS-PA isolation, with an odds
ratio of 6.9 (95% CI, 2.5–18.6). Age was not associated with
CRUS-PA isolation, nor was community acquisition (specimens
TABLE 1. Characteristics of case and control patients and
their respective Pseudomonas aeruginosa-positive cultures
Characteristics Case (n = 800) Control (n = 800) p-Value
Specimen type
Blood 53 (6.6%) 56 (8%) 0.843
Sputum 340 (43%) 274 (34%) 0.001
Wound 206 (26%) 185 (23%) 0.245
Urine 183 (23%) 236 (30%) 0.003
Community
acquired (3 days)a
115 (24%) 157 (33%) 0.001
Age 55  24 58  25 0.002
Albumin 24  6 25  6 0.101
Haemoglobin 9.5  1.4 9.4  2.2 0.725
WBC 15.4  8.5 16.3  13.2 0.53
Urea 18.5  13.6 15.6  12.4 0.05
Creatinine 193  183 157  140 0.043
aData available for 477 pairs.
TABLE 2. Sensitivity proﬁles of index specimensa
Antibiotics Cases (%) Controls (%) p-Value
Gentamicin 481 (60) 558 (70) <0.001
Amikacin 621 (78) 666 (83) 0.005
Ciproﬂoxacin 496 (62) 592 (74) <0.001
Oﬂoxacin 294 (37) 482 (60) <0.001
Colistin 796 (99) 795 (99) 0.31
Ceftazidime 667 (83) 691 (86) 0.08
Aztreonam 382 (48) 423 (53) 0.04
Ureidopenicillin 800 (100) 584 (73) –
Meropenem 0 (0) (n = 150) 139 (92) (n = 152) –
Imipenem 0 (0) (n = 650) 582 (90) (n = 648) –
aThe table presents the number (%) of sensitive specimens.
TABLE 3. Individual exposure to carbapenems and ureid-
openicillins in temporal relationship to index specimens
Temporal
relationship Antibiotics
Cases
(%)
Controls
(%) p-Value
On index date Ertapenem 24 (3) 9 (1) 0.002
Meropenem/
imipenem
119 (15) 30 (3.8) <0.001
Ureidopenicillins 30 (3.8) 20 (2.5) 0.203
Prior to index
date – anytime
Ertapenem 90 (11) 19 (2.4) <0.001
Meropenem/
imipenem
336 (42) 77 (9.6) <0.001
Ureidopenicillins 268 (33.5) 152 (19) <0.001
Prior to index date
– previous month
Ertapenem 70 (9) 16 (2) <0.001
Meropenem/
imipenem
204 (25.5) 37 (4.6) <0.001
Ureidopenicillins 152 (19) 79 (9.9) <0.001
Prior to index date
– previous 6 months
Ertapenem 87 (11) 19 (2.5) <0.001
Meropenem/
imipenem
248 (31) 46 (5.8) <0.001
Ureidopenicillins 218 (27.3) 100 (12.5) <0.001
After index date
– anytime
Ertapenem 69 (9) 36 (4.5) <0.001
Meropenem/
imipenem
289 (36.1) 115 (14.4) <0.001
Ureidopenicillins 255 (31.9) 185 (23.1) <0.001
After index date
– following month
Ertapenem 39 (5) 22 (2.8) 0.027
Meropenem/
imipenem
156 (19.5) 76 (9.5) <0.001
Ureidopenicillins 159 (19.9) 110 (13.8) 0.001
After index date
– following 6 months
Ertapenem 54 (6.8) 25 (3.1) <0.001
Meropenem/
imipenem
192 (24) 86 (10.8) <0.001
Ureidopenicillins 201 (25.1) 131 (16.4) <0.001
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collected up to 72 h from admission or later) vs. nosocomial
acquisition. Neither prior ureidopenicillin nor ertapenem
regimens showed an association with CRUS-PA isolation.
Similarly, other antibiotic prescriptions (aminoglycosides, qui-
nolones and colistin) were not associated with CRUS-PA
isolation.
The mortality among CRUS-PA patients was similar to that
of the controls (Fig. 3a). However, control patients with
CRUR-PA index specimens had poorer survival compared
with all case patients and other control patients (Fig. S3). We
were intrigued by this because subsequent CRUR-PA isolation
was more common among CRUS-PA patients compared with
controls who did not start with CRUR-PA (Fig. 3b). Thus, in
order to further understand if CRUS-PA was associated with
either increased mortality and/or increased likelihood of future
CRUR-PA isolation we used a stratiﬁed Cox proportional
hazard time-dependent regression model. The case patients
had a similar overall mortality rate to controls: hazard ratio
(HR) of 0.8 (0.6–1.1). This was also true for patients with
subsequent isolation of CRUR-PA, HR 0.8 (0.3–1.9), suggesting
that even when a CRUR-PA phenotype was subsequently
isolated from the CRUS-PA case patients, the survival
outcome for those patients had not changed.
As we found that prior use of carbapenems is associated
with isolation of CRUS-PA, and a signiﬁcant proportion of
CRUS-PA patients had later isolation of CRUR-PA, we
explored the possible association of antibiotic treatment with
the subsequent isolation of CRUR-PA among the CRUS-PA
patients. Surprisingly, patients who received ertapenem (a
carbapenem that is not considered to be clinically effective for
PA), as opposed to any other antibiotic, demonstrated a
unique phenomenon. Speciﬁcally, the risk of eventual
CRUR-PA isolation was increased among CRUS-PA patients
who received ertapenem after the index specimen date and
not prior to that date (HR, 1.9; 95% CI, 1.01–3.4). We did not
ﬁnd any similar pattern with other antibiotics, such as
imipenem/meropenem, ureidopenicillins, colistin, aminoglyco-
sides and quinolones (Fig. 4). This suggests a unique associa-
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FIG. 2. Frequency distribution of antibiotic exposure in temporal relation to the index specimen date. Cases are on the right pyramid (green) and
controls are on the left (blue). (a) Distribution of antipseudomonal carbapenems (imipenem/meropenem). X-axis ranges between 0 and 220 days. (b)
Distribution of ertapenem. X-axis ranges between 0 and 45 days. (c) Distribution of ureidopenicillin antibiotics. X-axis ranges between 0 and 45 days.
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tion between exposure to the non-PA carbapenem and future
isolation of CRUR-PA.
As mentioned above, subsequent isolation of CRUR-PA was
far less common among control patients. Among control
patients with a carbapenem-sensitive ureidopenicillin-sensitive
(CSUS) PA (n = 554), there were 62 (11%) subsequent
ureidopenicillin-resistant isolates. Unlike the evolution to
CRUR-PA in a CRUS-PA patient, we did not found an
association between ertapenem and carbapenem use and
CRUR-PA evolvement in CSUS-PA controls. Nevertheless,
ureidopenicillin use was associated with the subsequent
isolation of ureidopenicillin-resistant PA among these
CSUS-PA patients (p 0.038).
Not all patients (156, 16.3%) from whom CRUS-PA was
isolated were included in the analysis due to lack of matching
controls. We assessed whether the exclusion of those
non-matched CRUS-PA patients had potentially biased our
results. Indeed, non-matched CRUS-PA patients were com-
monly from the Mt Scopus campus (42% vs. 12%,
p-value <0.001), the surgical subspecialty wards (24% vs.
16%) and pediatrics (22% vs. 6%), and less commonly from
intensive care units (11% vs. 42%, p-value <0.001). The
non-included CRUS-PA-positive patients were, on average,
12 years younger than the included CRUS-PA-positive patients
(p-value <0.001). There was no difference in the sex and year
of presentation between the included and non-included cases.
Discussion
Carbapenem-resistant PA isolates emerged during the last
decade of the 20th century. A subgroup of these demonstrated
a susceptibility to ureidopenicillins (CRUS-PA). There are
reports in which CRUS-PA was identiﬁed in as many as 40–
80% of carbapenem-resistant PA isolates [10–12].
In this report we used this PA resistance phenotype to
study the effect of antibiotic selection pressure on the
development of resistance patterns. We found that exposure
to carbapenems is greater among cases, both before and after
index specimens. Antibiotic exposure was associated with
subsequent isolation of CRUR-PA among CRUS-PA patients.
Most notably, ertapenem exposure after the isolation of
CRUS-PA, but not before, was predictive of CRUR-PA
isolation among the cases.
In line with our ﬁndings, it was previously shown that
consumption of antibiotics is well associated with increased
microbial resistance [13–17], including PA resistance [4,18].
Restriction of antibiotic use has also been shown to decrease
resistance [19,20]. That is a main reason for wide implementa-
tion of antibiotic stewardship programmes [6,7]. PA is consid-
ered inherently resistant to ertapenem. Thus, it was presumed
that the introduction of ertapenem into clinical use would delay
the emergence of carbapenem resistance in PAor even decrease
it [21–23]. Indeed, there are some studies suggesting that
ertapenem is not associated with increased carbapenem resis-
tance in PA [24–26]. However, those reports drew their
conclusions from analysis of collections of isolates and grouped
antibiotic usage (ecological analyses), and there was no direct
analytical connection between the patients from whom PA
(a)
(b)
(c)
FIG. 3. Survival of patients and acquisition of resistant Pseudomonas
aeruginosa (PA). (a) Kaplan–Meier survival curves. Cases (blue line) vs.
controls (orange line); p-values arewith borderline statistical signiﬁcance
depending on method: log-rank 0.026, Breslow 0.071, Tarone-Ware
0.046. (b) Acquisition of carbapenem-resistant ureidopenicillin-resistant
PA (CRUR-PA) since index date (CRUS-PA, blue line; carbapenem-sen-
sitive ureidopenicillin-sensitive PA, grey line; carbapenem-sensitive
ureidopenicillin-resistant PA, dark blue line). All three curves are
signiﬁcantly different one from the other (p-value <0.05).
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specimens were collected and thosewho received antibiotics. In
contrast, our study overcame this limitation by using a
patient-centred methodology and not an ecological analysis.
Patient-centred analyses are more difﬁcult to perform and
are far less common than ecological analyses. Johnson et al. [5]
demonstrated that a signiﬁcant proportion of ICU-associated
imipenem-resistant PA was acquired via patient-to-patient
transmission. There was no assessment of the role of antibiotic
exposure, though some imipenem-susceptible PA pulsotypes
became imipenem resistant, suggesting either evolutionary
pressure or horizontal transfer [5]. Another study in a tertiary
care centre demonstrated that among 142 imipenem-resistant
PA-carrying patients, quinolone exposure was more prevalent
than in patients with imipenem-susceptible PA [10]. In a
case-control study examining risk factors for acquisition of
extended-spectrum drug-resistant PA, Park et al. [27] did not
ﬁnd among the 33 cases that prior antibiotic exposure was
more prevalent. A previous Israeli case-control report found
that 82 multidrug-resistant PA-carrying patients were more
often treated with prior broad-spectrum antibiotics [28]. In a
study assessing different deﬁnitions of antibiotic exposure,
ureidopenicillin resistance was associated with prior exposure
to any antibiotics, depending on the cumulative burden of prior
exposures [29]. Our study is far larger than these previous
analyses and presents patient-unique data spanning two
decades.
In vitro, antibiotic exposure has been linked to changes in
resistance mechanisms. Antibiotics have been shown to induce
enzyme-mediated resistance [30], but other mechanisms may
exist.
Our study has certain limitations. Molecular studies cannot
be performed because most PA isolates are not preserved
routinely. Such analyses might provide insight into mechanisms
of resistance. Another possibility is that a substantial number
of CRUS-PA specimens, for clinical purposes, are pan-beta-lac-
tam resistant and ertapenem merely unveils this phenotype.
(a)
(b)
FIG. 4. Acquisition of carbapenem-resistant ureidopenicillin-resistant Pseudomonas aeruginosa (CRUR-PA) among carbapenem-resistant ureid-
openicillin-susceptible PA (CRUS-PA) cases, according to the type of antibiotic exposure in a 6-month period. No antibiotic exposure prior to and
after the index date, black line; antibiotic exposure only prior to the index date, orange line; antibiotic exposure only after the index date, blue line;
antibiotic exposure before and after the index date, green line.
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We are not aware of previous observations demonstrating
selection of resistance to other drugs by ertapenem.
Selective information bias poses a threat to the validity and
reliability of retrolective analyses such as ours. All data used
for analyses were based on computerized records, reducing
the potential for non-systematic information bias.
Computerized records themselves are limited and patient ﬁle
review might have led to insights into the clinicians’ reasoning
for choice of speciﬁc antimicrobials. Another possible draw-
back could result from the fact that antibiotic dispensing in the
emergency room in our hospitals was not documented on the
computerized database. These accounts for no more than a
day of undocumented care and continuation of treatment in
the inpatient wards have always been monitored by the
antibiotic stewardship programme. Most of the antibiotics
examined are not available outside the hospital setting, with
the exception of oral ﬂuoroquinolones. Thus, our assessment
of the effect of quinolone might be ﬂawed to some degree.
The patients included in this study might have received
antibiotic medications, prior to hospital admittance and after
discharge, which we could not account for. Unaccounted for
antibiotic exposure could lead to confounding of the presented
results; however, antibiotic dispensing would need to be
differently distributed between the cases and the controls,
which is unlikely as they had similar demographic and medical
proﬁles.
Another result worth noting is the fact that patients, in both
case and control groups, had received antibiotics to which the
PA isolated was resistant after the index date. This might
reﬂect consideration of other isolates that were felt to be
clinically signiﬁcant and, possibly, medical errors. However, we
have no reason to believe that these additional isolates were
differentially distributed between the cases and the controls,
given their matching.
To conclude, we have conducted a large and comprehensive
study assessing patient-speciﬁc relationships between antibi-
otic exposure and PA resistance phenotypes. We conﬁrmed
that antibiotics are associated with differential resistance
phenotypes and also provide a possible association of ertape-
nem with sequentially appearing PA resistance patterns.
Clinicians should be aware that CRUS-PA may be pan-beta-lac-
tam resistant and the use of antibiotics other than ureidopen-
icillins might be prudent.
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